Description
YM-155 is an inhibitor of survivin, an inhibitor of apoptosis protein (IAP) that displays anticancer chemotherapeutic activity. YM-155 is currently undergoing clinical trials and shows efficacy in the treatment of prostate cancer. YM-155 induces apoptosis in cellular models of neuroblastoma and inhibits tumor growth in vivo. Additionally, this compound downregulates expression of Mcl-1 and increases activation of caspases 3 and 8, suppressing cell growth in leukemia cells.